Hepion Pharmaceuticals Inc at ThinkEquity Conference Transcript
I'm Ryan Starkes, Partner and Life Science Leader for Centri. We're an accounting, valuation, and advisory firm focusing on supporting companies through their endeavors into the capital markets in those respective areas. Speaking on behalf of Hepion Pharmaceuticals is Robert Foster, CEO. Robert?
Thank you.
Good afternoon, everybody. I'm Robert Foster, CEO of Hepion Pharmaceuticals. We're headquartered in Edison, New Jersey, and we have laboratory facilities in Edmonton, Canada. So what I'd like to talk to you about today is our lead drug candidate called rencofilstat which is being positioned as an antifibrotic molecule. And the lead indication that we're chasing after is NASH, I'll give you some information about NASH here in a minute, as well as HCC which is the most common form of liver cancer.
So of course, I'm sure by this time you've seen a lot of these slides. This is a forward-looking statement, which I would encourage people to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
